AP657A - Indole derivatives as 5-HT receptor antagonist. - Google Patents
Indole derivatives as 5-HT receptor antagonist. Download PDFInfo
- Publication number
- AP657A AP657A APAP/P/1997/001036A AP9701036A AP657A AP 657 A AP657 A AP 657A AP 9701036 A AP9701036 A AP 9701036A AP 657 A AP657 A AP 657A
- Authority
- AP
- ARIPO
- Prior art keywords
- methoxy
- indoline
- trifluoromethyl
- pyrid
- pyridyl
- Prior art date
Links
- 150000002475 indoles Chemical class 0.000 title description 2
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 239000003420 antiserotonin agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 172
- 238000000034 method Methods 0.000 claims abstract description 80
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 58
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 6
- 125000004429 atom Chemical group 0.000 claims abstract description 5
- 125000003118 aryl group Chemical group 0.000 claims abstract description 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims abstract description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims abstract description 3
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 3
- -1 Ci.galkoxy Chemical group 0.000 claims description 100
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 84
- MCSWKSCZARDPJX-UHFFFAOYSA-N 5-methoxy-6-(trifluoromethyl)-2,3-dihydro-1h-indole Chemical compound C1=C(C(F)(F)F)C(OC)=CC2=C1NCC2 MCSWKSCZARDPJX-UHFFFAOYSA-N 0.000 claims description 40
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000004414 alkyl thio group Chemical group 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 239000005864 Sulphur Substances 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
- 125000000524 functional group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 4
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 3
- GSQYHDORJZCDFN-UHFFFAOYSA-N 5-methylsulfanyl-n-[3-(2-pyridin-3-yl-1,3-thiazol-4-yl)phenyl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(SC)=CC=2CCN1C(=O)NC(C=1)=CC=CC=1C(N=1)=CSC=1C1=CC=CN=C1 GSQYHDORJZCDFN-UHFFFAOYSA-N 0.000 claims description 3
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 3
- 125000001589 carboacyl group Chemical group 0.000 claims description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- UFHBEUMQHYZRLT-UHFFFAOYSA-N 5-methylsulfanyl-n-(6-phenoxypyridin-3-yl)-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(SC)=CC=2CCN1C(=O)NC(C=N1)=CC=C1OC1=CC=CC=C1 UFHBEUMQHYZRLT-UHFFFAOYSA-N 0.000 claims description 2
- RECDLRRCAGXVMZ-UHFFFAOYSA-N 6-chloro-5-methyl-n-(4-methyl-3-pyridin-3-ylphenyl)-2,3-dihydroindole-1-carboxamide Chemical compound CC1=CC=C(NC(=O)N2C3=CC(Cl)=C(C)C=C3CC2)C=C1C1=CC=CN=C1 RECDLRRCAGXVMZ-UHFFFAOYSA-N 0.000 claims description 2
- WJLZRVFPCNRCKU-UHFFFAOYSA-N 6-chloro-5-methyl-n-[4-methyl-3-(4-methylpyridin-3-yl)phenyl]-2,3-dihydroindole-1-carboxamide Chemical compound CC1=CC=NC=C1C1=CC(NC(=O)N2C3=CC(Cl)=C(C)C=C3CC2)=CC=C1C WJLZRVFPCNRCKU-UHFFFAOYSA-N 0.000 claims description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 2
- 229910006095 SO2F Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000019256 formaldehyde Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 2
- XCBITNZSYILANP-UHFFFAOYSA-N 5-methoxy-n-(1-pyridin-3-ylindol-5-yl)-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(C=C1C=C2)=CC=C1N2C1=CC=CN=C1 XCBITNZSYILANP-UHFFFAOYSA-N 0.000 claims 1
- PTSQKGMZHRDEEV-UHFFFAOYSA-N 5-methoxy-n-(2-pyrazin-2-yl-1,3-thiazol-4-yl)-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(N=1)=CSC=1C1=CN=CC=N1 PTSQKGMZHRDEEV-UHFFFAOYSA-N 0.000 claims 1
- RCKUMMWWCMFKRU-UHFFFAOYSA-N 5-methoxy-n-(4-methoxy-3-pyridin-3-ylphenyl)-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound COC1=CC=C(NC(=O)N2C3=CC(=C(OC)C=C3CC2)C(F)(F)F)C=C1C1=CC=CN=C1 RCKUMMWWCMFKRU-UHFFFAOYSA-N 0.000 claims 1
- GYCWCSSBHBSLLK-UHFFFAOYSA-N 5-methoxy-n-(6-pyridin-3-yloxypyridin-3-yl)-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(C=N1)=CC=C1OC1=CC=CN=C1 GYCWCSSBHBSLLK-UHFFFAOYSA-N 0.000 claims 1
- UAJJQZFBNVGDRP-UHFFFAOYSA-N 5-methoxy-n-[1-(pyridin-3-ylmethyl)indol-5-yl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(C=C1C=C2)=CC=C1N2CC1=CC=CN=C1 UAJJQZFBNVGDRP-UHFFFAOYSA-N 0.000 claims 1
- MYOUXGFVCPLGBA-UHFFFAOYSA-N 5-methylsulfanyl-n-[3-(pyridin-4-ylcarbamoyl)phenyl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(SC)=CC=2CCN1C(=O)NC(C=1)=CC=CC=1C(=O)NC1=CC=NC=C1 MYOUXGFVCPLGBA-UHFFFAOYSA-N 0.000 claims 1
- URQUXLQPBSERKS-UHFFFAOYSA-N 5-methylsulfanyl-n-[4-(2-pyridin-3-yl-1,3-thiazol-4-yl)phenyl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(SC)=CC=2CCN1C(=O)NC(C=C1)=CC=C1C(N=1)=CSC=1C1=CC=CN=C1 URQUXLQPBSERKS-UHFFFAOYSA-N 0.000 claims 1
- HDOVEAWGCHESLF-UHFFFAOYSA-N n-(3-bromo-4-methyl-5-pyridin-3-ylphenyl)-5-methoxy-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(C=1)=CC(Br)=C(C)C=1C1=CC=CN=C1 HDOVEAWGCHESLF-UHFFFAOYSA-N 0.000 claims 1
- NIHPOZNNOSDBPX-UHFFFAOYSA-N n-[5-(2,6-difluorophenyl)pyridin-3-yl]-5-methoxy-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(C=1)=CN=CC=1C1=C(F)C=CC=C1F NIHPOZNNOSDBPX-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 208000019901 Anxiety disease Diseases 0.000 abstract description 3
- 230000036506 anxiety Effects 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 224
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 137
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 125
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
- 239000007787 solid Substances 0.000 description 89
- 239000000203 mixture Substances 0.000 description 78
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 72
- 239000000243 solution Substances 0.000 description 68
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 67
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- 235000019439 ethyl acetate Nutrition 0.000 description 42
- 229940093499 ethyl acetate Drugs 0.000 description 41
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 37
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 25
- 239000008186 active pharmaceutical agent Substances 0.000 description 24
- 238000010992 reflux Methods 0.000 description 23
- 239000000284 extract Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 21
- 229910052786 argon Inorganic materials 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- 239000003208 petroleum Substances 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- OPSIJIHZUVULGY-UHFFFAOYSA-N 1-(trifluoromethyl)-2,3-dihydroindole Chemical compound C1=CC=C2N(C(F)(F)F)CCC2=C1 OPSIJIHZUVULGY-UHFFFAOYSA-N 0.000 description 16
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 16
- 229960004756 ethanol Drugs 0.000 description 15
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 15
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 238000001816 cooling Methods 0.000 description 14
- DVFKRWUIYPFWHQ-UHFFFAOYSA-N 5-methylsulfanyl-6-(trifluoromethyl)-2,3-dihydro-1h-indole Chemical compound C1=C(C(F)(F)F)C(SC)=CC2=C1NCC2 DVFKRWUIYPFWHQ-UHFFFAOYSA-N 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 238000001035 drying Methods 0.000 description 11
- 238000003818 flash chromatography Methods 0.000 description 11
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 9
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 9
- 125000004076 pyridyl group Chemical group 0.000 description 9
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- 239000007832 Na2SO4 Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 6
- HCGYMSSYSAKGPK-UHFFFAOYSA-N 2-nitro-1h-indole Chemical compound C1=CC=C2NC([N+](=O)[O-])=CC2=C1 HCGYMSSYSAKGPK-UHFFFAOYSA-N 0.000 description 6
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 6
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- WWBVZCBWSHFMLP-UHFFFAOYSA-N 6-(trifluoromethyl)-2,3-dihydro-1h-indole Chemical compound FC(F)(F)C1=CC=C2CCNC2=C1 WWBVZCBWSHFMLP-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 150000001540 azides Chemical class 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- UQIRNFWEYGHLFN-UHFFFAOYSA-N 3-[[5-methylsulfanyl-6-(trifluoromethyl)-2,3-dihydroindole-1-carbonyl]amino]benzoic acid Chemical compound C1=2C=C(C(F)(F)F)C(SC)=CC=2CCN1C(=O)NC1=CC=CC(C(O)=O)=C1 UQIRNFWEYGHLFN-UHFFFAOYSA-N 0.000 description 4
- DZEIKJMNXHOFHL-UHFFFAOYSA-N 3-pyrimidin-5-ylaniline Chemical compound NC1=CC=CC(C=2C=NC=NC=2)=C1 DZEIKJMNXHOFHL-UHFFFAOYSA-N 0.000 description 4
- JZIGUWAAZINEDW-UHFFFAOYSA-N 4-nitro-1-oxido-2-pyridin-3-yloxypyridin-1-ium Chemical compound [O-][N+](=O)C1=CC=[N+]([O-])C(OC=2C=NC=CC=2)=C1 JZIGUWAAZINEDW-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000001117 sulphuric acid Substances 0.000 description 4
- 235000011149 sulphuric acid Nutrition 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- QSWJNEMCJSPEHE-UHFFFAOYSA-N 2-pyridin-3-yl-1,3-thiazole-4-carbonyl azide Chemical compound [N-]=[N+]=NC(=O)C1=CSC(C=2C=NC=CC=2)=N1 QSWJNEMCJSPEHE-UHFFFAOYSA-N 0.000 description 3
- NQPTZDNPCHRUKQ-UHFFFAOYSA-N 3-fluoro-5-pyrimidin-5-ylbenzoyl azide Chemical compound FC1=CC(C(=O)N=[N+]=[N-])=CC(C=2C=NC=NC=2)=C1 NQPTZDNPCHRUKQ-UHFFFAOYSA-N 0.000 description 3
- VNUMPKFIXAZUJD-UHFFFAOYSA-N 4-fluoro-3-pyridin-3-ylbenzoyl azide Chemical compound FC1=CC=C(C(=O)N=[N+]=[N-])C=C1C1=CC=CN=C1 VNUMPKFIXAZUJD-UHFFFAOYSA-N 0.000 description 3
- HRALXSSCXYCKIN-UHFFFAOYSA-N 7-pyridin-3-yl-2,3-dihydro-1-benzofuran-5-amine Chemical compound C=1C(N)=CC=2CCOC=2C=1C1=CC=CN=C1 HRALXSSCXYCKIN-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- YPBAZSGPFZUAOT-UHFFFAOYSA-N ethyl 3-[[5-methylsulfanyl-6-(trifluoromethyl)-2,3-dihydroindole-1-carbonyl]amino]benzoate Chemical compound CCOC(=O)C1=CC=CC(NC(=O)N2C3=CC(=C(SC)C=C3CC2)C(F)(F)F)=C1 YPBAZSGPFZUAOT-UHFFFAOYSA-N 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- XNQMXAOWNIYMOX-UHFFFAOYSA-N phenyl n-(3-bromo-5-pyridin-3-ylphenyl)carbamate Chemical compound C=1C(C=2C=NC=CC=2)=CC(Br)=CC=1NC(=O)OC1=CC=CC=C1 XNQMXAOWNIYMOX-UHFFFAOYSA-N 0.000 description 3
- VHHSXTMSVQGBCZ-UHFFFAOYSA-N phenyl n-(3-fluoro-4-methoxy-5-pyridin-3-ylphenyl)carbamate Chemical compound C1=C(C=2C=NC=CC=2)C(OC)=C(F)C=C1NC(=O)OC1=CC=CC=C1 VHHSXTMSVQGBCZ-UHFFFAOYSA-N 0.000 description 3
- FALSTSYOYZXLBM-UHFFFAOYSA-N phenyl n-(3-fluoro-5-pyridin-3-ylphenyl)carbamate Chemical compound C=1C(C=2C=NC=CC=2)=CC(F)=CC=1NC(=O)OC1=CC=CC=C1 FALSTSYOYZXLBM-UHFFFAOYSA-N 0.000 description 3
- ROLBIVHOVWGRPJ-UHFFFAOYSA-N phenyl n-[3-(4-methylpyridin-3-yl)phenyl]carbamate Chemical compound CC1=CC=NC=C1C1=CC=CC(NC(=O)OC=2C=CC=CC=2)=C1 ROLBIVHOVWGRPJ-UHFFFAOYSA-N 0.000 description 3
- OTSLIYAPHNEBHW-UHFFFAOYSA-N phenyl n-[4-methyl-3-(4-methylpyridin-3-yl)phenyl]carbamate Chemical compound CC1=CC=NC=C1C1=CC(NC(=O)OC=2C=CC=CC=2)=CC=C1C OTSLIYAPHNEBHW-UHFFFAOYSA-N 0.000 description 3
- WXRFKWWSNPJOJB-UHFFFAOYSA-N phenyl n-[5-methyl-2-(1,2,4-oxadiazol-3-yl)phenyl]carbamate Chemical compound C=1C=CC=CC=1OC(=O)NC1=CC(C)=CC=C1C=1N=CON=1 WXRFKWWSNPJOJB-UHFFFAOYSA-N 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- KAMRUHHCLSYNFU-UHFFFAOYSA-N (3-nitrophenyl)-pyridin-3-ylmethanone Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)C=2C=NC=CC=2)=C1 KAMRUHHCLSYNFU-UHFFFAOYSA-N 0.000 description 2
- ASXFMIDIRZPCGK-UHFFFAOYSA-N (4-methylpyridin-3-yl)boronic acid Chemical compound CC1=CC=NC=C1B(O)O ASXFMIDIRZPCGK-UHFFFAOYSA-N 0.000 description 2
- ZWNCJCPLPUBNCZ-UHFFFAOYSA-N 1,2-dimethoxyethane;hydrate Chemical compound O.COCCOC ZWNCJCPLPUBNCZ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- RNTCWULFNYNFGI-UHFFFAOYSA-N 1-(2,3-dihydroindol-1-yl)ethanone Chemical compound C1=CC=C2N(C(=O)C)CCC2=C1 RNTCWULFNYNFGI-UHFFFAOYSA-N 0.000 description 2
- WDUVPNWQGFFLIF-UHFFFAOYSA-N 1-methoxy-6-(trifluoromethyl)-2,3-dihydroindole Chemical compound C1=C(C(F)(F)F)C=C2N(OC)CCC2=C1 WDUVPNWQGFFLIF-UHFFFAOYSA-N 0.000 description 2
- JULUAUZIVDSBND-UHFFFAOYSA-N 1-pyridin-4-ylindol-5-amine Chemical compound C1=CC2=CC(N)=CC=C2N1C1=CC=NC=C1 JULUAUZIVDSBND-UHFFFAOYSA-N 0.000 description 2
- IANAREFPKLOIAF-UHFFFAOYSA-N 2-[5-methoxy-2-nitro-4-(trifluoromethyl)phenyl]acetonitrile Chemical compound COC1=CC(CC#N)=C([N+]([O-])=O)C=C1C(F)(F)F IANAREFPKLOIAF-UHFFFAOYSA-N 0.000 description 2
- CGUOPPPIULULIN-UHFFFAOYSA-N 2-pyridin-3-yloxypyridin-4-amine Chemical compound NC1=CC=NC(OC=2C=NC=CC=2)=C1 CGUOPPPIULULIN-UHFFFAOYSA-N 0.000 description 2
- ROXMEGSVJDLDHD-UHFFFAOYSA-N 3-amino-n-pyridin-3-ylbenzamide Chemical compound NC1=CC=CC(C(=O)NC=2C=NC=CC=2)=C1 ROXMEGSVJDLDHD-UHFFFAOYSA-N 0.000 description 2
- RAGFYHJTQKWYKZ-UHFFFAOYSA-N 3-amino-n-pyridin-3-ylbenzenesulfonamide Chemical compound NC1=CC=CC(S(=O)(=O)NC=2C=NC=CC=2)=C1 RAGFYHJTQKWYKZ-UHFFFAOYSA-N 0.000 description 2
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 2
- UVDGDGFCTXUHSV-UHFFFAOYSA-N 4-methyl-3-pyridin-3-ylaniline Chemical compound CC1=CC=C(N)C=C1C1=CC=CN=C1 UVDGDGFCTXUHSV-UHFFFAOYSA-N 0.000 description 2
- CTLBRTCGGTWOTQ-UHFFFAOYSA-N 5-nitro-1-(pyridin-4-ylmethyl)indole Chemical compound C1=CC2=CC([N+](=O)[O-])=CC=C2N1CC1=CC=NC=C1 CTLBRTCGGTWOTQ-UHFFFAOYSA-N 0.000 description 2
- KEIHCLVBEDSLQS-UHFFFAOYSA-N 5-nitro-1-pyridin-3-ylindole Chemical compound C1=CC2=CC([N+](=O)[O-])=CC=C2N1C1=CC=CN=C1 KEIHCLVBEDSLQS-UHFFFAOYSA-N 0.000 description 2
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 2
- VNTXBOJIESFBJS-UHFFFAOYSA-N 6-(2-methylpyridin-3-yl)oxypyridin-3-amine Chemical compound CC1=NC=CC=C1OC1=CC=C(N)C=N1 VNTXBOJIESFBJS-UHFFFAOYSA-N 0.000 description 2
- YGWSGSCQMYIFRQ-UHFFFAOYSA-N 6-pyridin-3-yloxypyridin-3-amine Chemical compound N1=CC(N)=CC=C1OC1=CC=CN=C1 YGWSGSCQMYIFRQ-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004533 benzofuran-5-yl group Chemical group O1C=CC2=C1C=CC(=C2)* 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960004979 fampridine Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 208000003906 hydrocephalus Diseases 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- JMZFEHDNIAQMNB-UHFFFAOYSA-N m-aminophenylboronic acid Chemical compound NC1=CC=CC(B(O)O)=C1 JMZFEHDNIAQMNB-UHFFFAOYSA-N 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BQWSKMPPVQRNQG-UHFFFAOYSA-N phenyl n-(3-phenyl-5-pyridin-3-ylphenyl)carbamate Chemical compound C=1C=CC=CC=1OC(=O)NC(C=1)=CC(C=2C=CC=CC=2)=CC=1C1=CC=CN=C1 BQWSKMPPVQRNQG-UHFFFAOYSA-N 0.000 description 2
- SDBPWHDOWAKIJH-UHFFFAOYSA-N phenyl n-(6-pyridin-3-ylpyridin-3-yl)carbamate Chemical compound C=1C=CC=CC=1OC(=O)NC(C=N1)=CC=C1C1=CC=CN=C1 SDBPWHDOWAKIJH-UHFFFAOYSA-N 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- KTOYYOQOGAZUHV-UHFFFAOYSA-N s-acetylsulfanyl ethanethioate Chemical compound CC(=O)SSC(C)=O KTOYYOQOGAZUHV-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000002484 serotonin 2C antagonist Substances 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- LIGBGEJPUQBLTG-UHFFFAOYSA-N 1-bromo-3-fluoro-5-(trifluoromethyl)benzene Chemical compound FC1=CC(Br)=CC(C(F)(F)F)=C1 LIGBGEJPUQBLTG-UHFFFAOYSA-N 0.000 description 1
- BFCFYVKQTRLZHA-UHFFFAOYSA-N 1-chloro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1Cl BFCFYVKQTRLZHA-UHFFFAOYSA-N 0.000 description 1
- PQELMSRMIVCIMP-UHFFFAOYSA-N 1-chloro-5-methyl-2,3-dihydroindole Chemical compound CC1=CC=C2N(Cl)CCC2=C1 PQELMSRMIVCIMP-UHFFFAOYSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- SKENTPREXNBZNB-UHFFFAOYSA-N 2,3-dihydro-1h-indole;hydrochloride Chemical compound Cl.C1=CC=C2NCCC2=C1 SKENTPREXNBZNB-UHFFFAOYSA-N 0.000 description 1
- WLFGGJFWKXTOGJ-UHFFFAOYSA-N 2,3-dihydroindol-1-amine Chemical compound C1=CC=C2N(N)CCC2=C1 WLFGGJFWKXTOGJ-UHFFFAOYSA-N 0.000 description 1
- YUGDKEWUYZXXRU-UHFFFAOYSA-N 2-(4-chlorophenoxy)acetonitrile Chemical compound ClC1=CC=C(OCC#N)C=C1 YUGDKEWUYZXXRU-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical group CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- GZHPNIQBPGUSSX-UHFFFAOYSA-N 2-bromo-1-(3-nitrophenyl)ethanone Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)CBr)=C1 GZHPNIQBPGUSSX-UHFFFAOYSA-N 0.000 description 1
- RZJOIMPUMMQKFR-UHFFFAOYSA-N 2-bromo-1-fluoro-4-(trifluoromethyl)benzene Chemical compound FC1=CC=C(C(F)(F)F)C=C1Br RZJOIMPUMMQKFR-UHFFFAOYSA-N 0.000 description 1
- XPOBLHHOXREWDD-UHFFFAOYSA-N 2-bromo-5-chloro-1h-imidazole Chemical compound ClC1=CNC(Br)=N1 XPOBLHHOXREWDD-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- YSTCMHHKDOVZDA-UHFFFAOYSA-N 2-chloro-4-nitro-1-oxidopyridin-1-ium Chemical compound [O-][N+](=O)C1=CC=[N+]([O-])C(Cl)=C1 YSTCMHHKDOVZDA-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- FVGINDDZLLHQKO-UHFFFAOYSA-N 2-pyrazin-2-yl-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2N=CC=NC=2)=N1 FVGINDDZLLHQKO-UHFFFAOYSA-N 0.000 description 1
- FOQFGMAZUTUELM-UHFFFAOYSA-N 2-pyridin-3-yl-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=NC=CC=2)=N1 FOQFGMAZUTUELM-UHFFFAOYSA-N 0.000 description 1
- COOQMBOJAAZEIR-UHFFFAOYSA-N 2-pyridin-4-yl-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=CN=CC=2)=N1 COOQMBOJAAZEIR-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- AQZDIKCNODUMNY-UHFFFAOYSA-N 3,5-dibromo-4-methylaniline Chemical compound CC1=C(Br)C=C(N)C=C1Br AQZDIKCNODUMNY-UHFFFAOYSA-N 0.000 description 1
- TYJGBMIGPRFXMD-UHFFFAOYSA-N 3-(2-pyridin-3-yl-1,3-thiazol-4-yl)aniline Chemical compound NC1=CC=CC(C=2N=C(SC=2)C=2C=NC=CC=2)=C1 TYJGBMIGPRFXMD-UHFFFAOYSA-N 0.000 description 1
- UZGLOGCJCWBBIV-UHFFFAOYSA-N 3-(chloromethyl)pyridin-1-ium;chloride Chemical compound Cl.ClCC1=CC=CN=C1 UZGLOGCJCWBBIV-UHFFFAOYSA-N 0.000 description 1
- NTEOIGNTMFIIPX-UHFFFAOYSA-N 3-bromo-5-pyridin-3-ylaniline Chemical compound NC1=CC(Br)=CC(C=2C=NC=CC=2)=C1 NTEOIGNTMFIIPX-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- UMRQEDFNPHUOHJ-UHFFFAOYSA-N 3-ethyl-5-pyridin-3-ylaniline Chemical compound CCC1=CC(N)=CC(C=2C=NC=CC=2)=C1 UMRQEDFNPHUOHJ-UHFFFAOYSA-N 0.000 description 1
- HTEPMXLKKDKDAQ-UHFFFAOYSA-N 3-fluoro-5-iodoaniline Chemical compound NC1=CC(F)=CC(I)=C1 HTEPMXLKKDKDAQ-UHFFFAOYSA-N 0.000 description 1
- NFIXYAVTGLYDLV-UHFFFAOYSA-N 3-fluoro-5-pyridin-3-ylaniline Chemical compound NC1=CC(F)=CC(C=2C=NC=CC=2)=C1 NFIXYAVTGLYDLV-UHFFFAOYSA-N 0.000 description 1
- NOQNUZSBDPKAJB-UHFFFAOYSA-N 3-fluoro-5-pyrimidin-5-ylbenzoic acid Chemical compound OC(=O)C1=CC(F)=CC(C=2C=NC=NC=2)=C1 NOQNUZSBDPKAJB-UHFFFAOYSA-N 0.000 description 1
- SUFBXXRIPSNILO-UHFFFAOYSA-N 3-nitro-n-pyridin-3-ylbenzamide Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)NC=2C=NC=CC=2)=C1 SUFBXXRIPSNILO-UHFFFAOYSA-N 0.000 description 1
- MWWNNNAOGWPTQY-UHFFFAOYSA-N 3-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(S(Cl)(=O)=O)=C1 MWWNNNAOGWPTQY-UHFFFAOYSA-N 0.000 description 1
- NXTNASSYJUXJDV-UHFFFAOYSA-N 3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=O)=C1 NXTNASSYJUXJDV-UHFFFAOYSA-N 0.000 description 1
- FIFJVOQZYRUYDX-UHFFFAOYSA-N 3-phenyl-5-pyridin-3-ylaniline Chemical compound C=1C(N)=CC(C=2C=CC=CC=2)=CC=1C1=CC=CN=C1 FIFJVOQZYRUYDX-UHFFFAOYSA-N 0.000 description 1
- YTJQJGKMRLQBJP-UHFFFAOYSA-N 3-pyridin-3-ylaniline Chemical compound NC1=CC=CC(C=2C=NC=CC=2)=C1 YTJQJGKMRLQBJP-UHFFFAOYSA-N 0.000 description 1
- BAQRBKUADMBZRT-UHFFFAOYSA-N 4-(3-nitrophenyl)-2-pyridin-3-yl-1,3-thiazole;hydrobromide Chemical compound Br.[O-][N+](=O)C1=CC=CC(C=2N=C(SC=2)C=2C=NC=CC=2)=C1 BAQRBKUADMBZRT-UHFFFAOYSA-N 0.000 description 1
- ZDHKVKPZQKYREU-UHFFFAOYSA-N 4-(chloromethyl)pyridine;hydron;chloride Chemical compound Cl.ClCC1=CC=NC=C1 ZDHKVKPZQKYREU-UHFFFAOYSA-N 0.000 description 1
- GYLBVAPFPIKDNV-UHFFFAOYSA-N 4-(pyridin-4-ylmethoxy)aniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=NC=C1 GYLBVAPFPIKDNV-UHFFFAOYSA-N 0.000 description 1
- RIOFBOIXVRXZRB-UHFFFAOYSA-N 4-(pyridin-4-ylmethylsulfanyl)aniline Chemical compound C1=CC(N)=CC=C1SCC1=CC=NC=C1 RIOFBOIXVRXZRB-UHFFFAOYSA-N 0.000 description 1
- COLXUKGEJNKESM-UHFFFAOYSA-N 4-(pyridin-4-ylsulfanylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CSC1=CC=NC=C1 COLXUKGEJNKESM-UHFFFAOYSA-N 0.000 description 1
- WONJHAUJJJJHMI-UHFFFAOYSA-N 4-(pyridin-4-ylsulfonylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CS(=O)(=O)C1=CC=NC=C1 WONJHAUJJJJHMI-UHFFFAOYSA-N 0.000 description 1
- HIHMQXQKWFZACD-UHFFFAOYSA-N 4-[[5-methylsulfanyl-6-(trifluoromethyl)-2,3-dihydroindole-1-carbonyl]amino]benzoic acid Chemical compound C1=2C=C(C(F)(F)F)C(SC)=CC=2CCN1C(=O)NC1=CC=C(C(O)=O)C=C1 HIHMQXQKWFZACD-UHFFFAOYSA-N 0.000 description 1
- MJYFVDNMTKLGTH-UHFFFAOYSA-N 4-bromo-6-(3,4-dichlorophenyl)sulfanyl-1-[[4-(dimethylcarbamoyl)phenyl]methyl]indole-2-carboxylic acid Chemical compound BrC1=C2C=C(N(C2=CC(=C1)SC1=CC(=C(C=C1)Cl)Cl)CC1=CC=C(C=C1)C(N(C)C)=O)C(=O)O MJYFVDNMTKLGTH-UHFFFAOYSA-N 0.000 description 1
- ZECCDLLQKKWPCG-UHFFFAOYSA-N 4-chloro-3-pyridin-3-ylaniline Chemical compound NC1=CC=C(Cl)C(C=2C=NC=CC=2)=C1 ZECCDLLQKKWPCG-UHFFFAOYSA-N 0.000 description 1
- VCZGIQMMLWMYEL-UHFFFAOYSA-N 4-methoxy-3-pyridin-3-ylaniline Chemical compound COC1=CC=C(N)C=C1C1=CC=CN=C1 VCZGIQMMLWMYEL-UHFFFAOYSA-N 0.000 description 1
- LPMRNRAVJLGSEB-UHFFFAOYSA-N 4-tert-butyl-3-pyridin-3-ylaniline Chemical compound CC(C)(C)C1=CC=C(N)C=C1C1=CC=CN=C1 LPMRNRAVJLGSEB-UHFFFAOYSA-N 0.000 description 1
- 229940116892 5 Hydroxytryptamine 2B receptor antagonist Drugs 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- DZNUXAXDALUDBZ-UHFFFAOYSA-N 5-(2,6-difluorophenyl)pyridine-3-carbonyl azide Chemical compound FC1=CC=CC(F)=C1C1=CN=CC(C(=O)N=[N+]=[N-])=C1 DZNUXAXDALUDBZ-UHFFFAOYSA-N 0.000 description 1
- GFGDNIXOJRCXGI-UHFFFAOYSA-N 5-[3-fluoro-5-(trifluoromethyl)phenyl]pyrimidine Chemical compound FC(F)(F)C1=CC(F)=CC(C=2C=NC=NC=2)=C1 GFGDNIXOJRCXGI-UHFFFAOYSA-N 0.000 description 1
- LBVLLEAKKBHEDJ-UHFFFAOYSA-N 5-bromopyridine-3-carbonyl azide Chemical compound BrC1=CN=CC(C(=O)N=[N+]=[N-])=C1 LBVLLEAKKBHEDJ-UHFFFAOYSA-N 0.000 description 1
- GYCPLYCTMDTEPU-UHFFFAOYSA-N 5-bromopyrimidine Chemical compound BrC1=CN=CN=C1 GYCPLYCTMDTEPU-UHFFFAOYSA-N 0.000 description 1
- TUKXLWDAMSYWIT-UHFFFAOYSA-N 5-methoxy-n-(6-pyridin-3-ylsulfanylpyridin-3-yl)-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(C=N1)=CC=C1SC1=CC=CN=C1 TUKXLWDAMSYWIT-UHFFFAOYSA-N 0.000 description 1
- XQLOSTOSGNWJET-UHFFFAOYSA-N 5-methoxy-n-[3-(pyridin-3-ylsulfamoyl)phenyl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(C=1)=CC=CC=1S(=O)(=O)NC1=CC=CN=C1 XQLOSTOSGNWJET-UHFFFAOYSA-N 0.000 description 1
- XCORDYHGLWTUMS-UHFFFAOYSA-N 5-methoxy-n-[4-(pyridin-4-ylmethoxy)phenyl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(C=C1)=CC=C1OCC1=CC=NC=C1 XCORDYHGLWTUMS-UHFFFAOYSA-N 0.000 description 1
- WBGZTUVFDUVQKY-UHFFFAOYSA-N 5-methoxy-n-[6-(2-methylpyridin-3-yl)oxypyridin-3-yl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(C=N1)=CC=C1OC1=CC=CN=C1C WBGZTUVFDUVQKY-UHFFFAOYSA-N 0.000 description 1
- IVIDCGBGPDBYIQ-UHFFFAOYSA-N 5-methoxy-n-[6-(4-methylpyridin-3-yl)oxypyridin-3-yl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(C=N1)=CC=C1OC1=CN=CC=C1C IVIDCGBGPDBYIQ-UHFFFAOYSA-N 0.000 description 1
- VUAISFVZIULHSD-UHFFFAOYSA-N 5-methoxy-n-[6-(pyridin-4-ylmethoxy)pyridin-3-yl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(C=N1)=CC=C1OCC1=CC=NC=C1 VUAISFVZIULHSD-UHFFFAOYSA-N 0.000 description 1
- HDOMQRSUIZCGPR-UHFFFAOYSA-N 5-methylsulfanyl-6-(trifluoromethyl)-2,3-dihydro-1h-indole;hydrochloride Chemical compound Cl.C1=C(C(F)(F)F)C(SC)=CC2=C1NCC2 HDOMQRSUIZCGPR-UHFFFAOYSA-N 0.000 description 1
- DLUDXFQJJRMRFQ-UHFFFAOYSA-N 5-methylsulfanyl-n-[4-(2-pyridin-4-yl-1,3-thiazol-4-yl)phenyl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(SC)=CC=2CCN1C(=O)NC(C=C1)=CC=C1C(N=1)=CSC=1C1=CC=NC=C1 DLUDXFQJJRMRFQ-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- GONIEUPXDUUNEZ-UHFFFAOYSA-N 6-(4-methylpyridin-3-yl)oxypyridin-3-amine Chemical compound CC1=CC=NC=C1OC1=CC=C(N)C=N1 GONIEUPXDUUNEZ-UHFFFAOYSA-N 0.000 description 1
- KWDYKIDWXMMEHC-UHFFFAOYSA-N 6-(6-methylpyridin-3-yl)oxypyridin-3-amine Chemical compound C1=NC(C)=CC=C1OC1=CC=C(N)C=N1 KWDYKIDWXMMEHC-UHFFFAOYSA-N 0.000 description 1
- GXZHBLPVUBGAIJ-UHFFFAOYSA-N 6-(pyridin-4-ylmethoxy)pyridin-3-amine Chemical compound N1=CC(N)=CC=C1OCC1=CC=NC=C1 GXZHBLPVUBGAIJ-UHFFFAOYSA-N 0.000 description 1
- ZAMJLADJGLXVOJ-UHFFFAOYSA-N 6-chloro-5-methyl-2,3-dihydro-1h-indole Chemical compound C1=C(Cl)C(C)=CC2=C1NCC2 ZAMJLADJGLXVOJ-UHFFFAOYSA-N 0.000 description 1
- DETKIRMPBJPJRQ-UHFFFAOYSA-N 6-phenoxypyridin-3-amine Chemical compound N1=CC(N)=CC=C1OC1=CC=CC=C1 DETKIRMPBJPJRQ-UHFFFAOYSA-N 0.000 description 1
- WSRUDRFDBGUFQN-UHFFFAOYSA-N 6-pyridin-3-ylsulfanylpyridin-3-amine Chemical compound N1=CC(N)=CC=C1SC1=CC=CN=C1 WSRUDRFDBGUFQN-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000272522 Anas Species 0.000 description 1
- 101000742062 Bos taurus Protein phosphatase 1G Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 235000008247 Echinochloa frumentacea Nutrition 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 101000761348 Homo sapiens 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- VNQABZCSYCTZMS-UHFFFAOYSA-N Orthoform Chemical compound COC(=O)C1=CC=C(O)C(N)=C1 VNQABZCSYCTZMS-UHFFFAOYSA-N 0.000 description 1
- 240000004072 Panicum sumatrense Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 101000761350 Rattus norvegicus 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000007080 aromatic substitution reaction Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000001626 borono group Chemical group [H]OB([*])O[H] 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- RCTFHBWTYQOVGJ-UHFFFAOYSA-N chloroform;dichloromethane Chemical compound ClCCl.ClC(Cl)Cl RCTFHBWTYQOVGJ-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- HMLKMUJGRHODCK-UHFFFAOYSA-N ethyl 4-[[5-methylsulfanyl-6-(trifluoromethyl)-2,3-dihydroindole-1-carbonyl]amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)N1C2=CC(C(F)(F)F)=C(SC)C=C2CC1 HMLKMUJGRHODCK-UHFFFAOYSA-N 0.000 description 1
- PCPIANOJERKFJI-UHFFFAOYSA-N ethyl 5-bromopyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=CC(Br)=C1 PCPIANOJERKFJI-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- PZJSZBJLOWMDRG-UHFFFAOYSA-N furan-2-ylboronic acid Chemical compound OB(O)C1=CC=CO1 PZJSZBJLOWMDRG-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002476 indolines Chemical class 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229950008693 mesulergine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- HQKREWDLUGAQEN-UHFFFAOYSA-N methyl 4-fluoro-3-pyridin-3-ylbenzoate Chemical compound COC(=O)C1=CC=C(F)C(C=2C=NC=CC=2)=C1 HQKREWDLUGAQEN-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- XTUFMBUGWUNIJA-UHFFFAOYSA-N n-(3-fluoro-4-methoxy-5-pyridin-3-ylphenyl)-5-methoxy-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(C=1)=CC(F)=C(OC)C=1C1=CC=CN=C1 XTUFMBUGWUNIJA-UHFFFAOYSA-N 0.000 description 1
- IZSOZODCXKOLMC-UHFFFAOYSA-N n-[3-fluoro-5-(4-methylpyridin-3-yl)phenyl]-5-methoxy-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(C(F)(F)F)C(OC)=CC=2CCN1C(=O)NC(C=1)=CC(F)=CC=1C1=CN=CC=C1C IZSOZODCXKOLMC-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- ZAUDCMFXYGDYMV-UHFFFAOYSA-N n-[4-(2-ethylpyridin-4-yl)phenyl]-5-methylsulfanyl-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide Chemical compound C1=NC(CC)=CC(C=2C=CC(NC(=O)N3C4=CC(=C(SC)C=C4CC3)C(F)(F)F)=CC=2)=C1 ZAUDCMFXYGDYMV-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 229950006098 orthocaine Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 1
- XQWBMZWDJAZPPX-UHFFFAOYSA-N pyridine-3-carbothioamide Chemical compound NC(=S)C1=CC=CN=C1 XQWBMZWDJAZPPX-UHFFFAOYSA-N 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 239000002891 serotonin 2B antagonist Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001391 thioamide group Chemical group 0.000 description 1
- 238000006365 thiocyanation reaction Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- DLTHSKKNYFFRAQ-UHFFFAOYSA-N tributyl-(2,6-difluorophenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=C(F)C=CC=C1F DLTHSKKNYFFRAQ-UHFFFAOYSA-N 0.000 description 1
- ZMCBYSBVJIMENC-UHFFFAOYSA-N tricaine Chemical compound CCOC(=O)C1=CC=CC(N)=C1 ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9502052.5A GB9502052D0 (en) | 1995-02-02 | 1995-02-02 | Novel compounds |
| GBGB9508327.5A GB9508327D0 (en) | 1995-04-25 | 1995-04-25 | Novel compounds |
| GBGB9508967.8A GB9508967D0 (en) | 1995-05-03 | 1995-05-03 | Novel compounds |
| GBGB9516845.6A GB9516845D0 (en) | 1995-08-17 | 1995-08-17 | Novel compounds |
| GBGB9517542.8A GB9517542D0 (en) | 1995-08-26 | 1995-08-26 | Novel compounds |
| GBGB9518574.0A GB9518574D0 (en) | 1995-09-12 | 1995-09-12 | Novel compounds |
| PCT/EP1996/000368 WO1996023783A1 (en) | 1995-02-02 | 1996-01-26 | Indole derivatives as 5-ht receptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9701036A0 AP9701036A0 (en) | 1997-07-31 |
| AP657A true AP657A (en) | 1998-08-06 |
Family
ID=27547235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1997/001036A AP657A (en) | 1995-02-02 | 1996-01-26 | Indole derivatives as 5-HT receptor antagonist. |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US5990133A (de) |
| EP (1) | EP0808312B1 (de) |
| JP (1) | JPH10513442A (de) |
| KR (1) | KR19980701879A (de) |
| CN (1) | CN1151147C (de) |
| AP (1) | AP657A (de) |
| AR (1) | AR002705A1 (de) |
| AT (1) | ATE197300T1 (de) |
| AU (1) | AU699727B2 (de) |
| BG (1) | BG101806A (de) |
| BR (1) | BR9607016A (de) |
| CA (1) | CA2212061A1 (de) |
| CZ (1) | CZ294097B6 (de) |
| DE (1) | DE69610822T2 (de) |
| DK (1) | DK0808312T3 (de) |
| EA (1) | EA000304B1 (de) |
| ES (1) | ES2151652T3 (de) |
| FI (1) | FI973205L (de) |
| GR (1) | GR3035075T3 (de) |
| HU (1) | HU223601B1 (de) |
| IL (1) | IL116998A (de) |
| MA (1) | MA23792A1 (de) |
| MY (1) | MY132229A (de) |
| NO (1) | NO313520B1 (de) |
| NZ (1) | NZ301265A (de) |
| OA (1) | OA10502A (de) |
| PL (1) | PL184490B1 (de) |
| PT (1) | PT808312E (de) |
| RO (1) | RO115522B1 (de) |
| SI (1) | SI0808312T1 (de) |
| SK (1) | SK103897A3 (de) |
| TR (1) | TR199700749T1 (de) |
| WO (1) | WO1996023783A1 (de) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1151147C (zh) * | 1995-02-02 | 2004-05-26 | 史密丝克莱恩比彻姆有限公司 | 作为5-ht受体拮抗剂的吲哚衍生物 |
| GB9517559D0 (en) * | 1995-08-26 | 1995-10-25 | Smithkline Beecham Plc | Novel compounds |
| GB9607219D0 (en) * | 1996-04-04 | 1996-06-12 | Smithkline Beecham Plc | Novel compounds |
| GB9612885D0 (en) * | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
| GB9612883D0 (en) * | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
| US6124289A (en) * | 1996-07-24 | 2000-09-26 | Dupont Pharmaceuticals Co. | Azolo triazines and pyrimidines |
| US7094782B1 (en) | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
| US6313124B1 (en) | 1997-07-23 | 2001-11-06 | Dupont Pharmaceuticals Company | Tetrazine bicyclic compounds |
| US6060478A (en) * | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| US6420541B1 (en) | 1998-04-14 | 2002-07-16 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| US6541209B1 (en) | 1997-04-14 | 2003-04-01 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| GB9710523D0 (en) * | 1997-05-23 | 1997-07-16 | Smithkline Beecham Plc | Novel compounds |
| AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| WO1999043650A2 (en) * | 1998-02-25 | 1999-09-02 | Smithkline Beecham Plc | Process(es) for the preparation of 6-trifluoromethyl-indoline derivatives |
| WO1999052927A1 (en) * | 1998-04-14 | 1999-10-21 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| US6140509A (en) * | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| US6150393A (en) * | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
| UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US6326385B1 (en) * | 1999-08-04 | 2001-12-04 | Icagen, Inc. | Methods for treating or preventing pain |
| AUPQ319899A0 (en) | 1999-10-01 | 1999-10-28 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2001000008A (es) * | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| WO2001068585A1 (en) * | 2000-03-14 | 2001-09-20 | Fujisawa Pharmaceutical Co., Ltd. | Novel amide compounds |
| US6448293B1 (en) | 2000-03-31 | 2002-09-10 | Pfizer Inc. | Diphenyl ether compounds useful in therapy |
| FR2807754A1 (fr) * | 2000-04-13 | 2001-10-19 | Adir | Nouveaux derives de cyclobuta-indole carboxamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2398446A1 (en) | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinases |
| GB0019950D0 (en) * | 2000-08-12 | 2000-09-27 | Smithkline Beecham Plc | Compounds |
| US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| US6610747B2 (en) | 2000-08-31 | 2003-08-26 | Pfizer Inc. | Phenoxybenzylamine derivatives as SSRIs |
| US6630504B2 (en) | 2000-08-31 | 2003-10-07 | Pfizer Inc. | Phenoxyphenylheterocyclyl derivatives as SSRIs |
| JP4160295B2 (ja) * | 2000-12-08 | 2008-10-01 | 武田薬品工業株式会社 | ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途 |
| US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
| US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| GB2380190A (en) * | 2001-08-28 | 2003-04-02 | Bayer Ag | Antiinflammatory heterocyclic sulphones |
| CA2462135C (en) | 2001-09-29 | 2014-12-30 | Lg Electronics Inc. | Method for transferring and /or receiving data in communication system and apparatus thereof |
| CA2466440A1 (en) | 2001-11-14 | 2003-05-22 | Schering Corporation | Cannabinoid receptor ligands |
| GB0200283D0 (en) * | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
| AU2003223467B2 (en) | 2002-04-08 | 2007-10-04 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| WO2003086403A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| AU2003243637A1 (en) | 2002-06-19 | 2004-01-06 | Schering Corporation | Cannabinoid receptor agonists |
| EP1545523A1 (de) * | 2002-07-03 | 2005-06-29 | Astex Technology Limited | 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINE UND IHRE ANALOGA ASP38 MAP KINASE-HEMMER |
| ATE375349T1 (de) | 2002-08-02 | 2007-10-15 | Merck & Co Inc | Substituierte furo(2,3-b)pyridin derivate |
| WO2004018463A2 (en) * | 2002-08-23 | 2004-03-04 | Rigel Pharmaceuticals, Inc. | Pyridyl substituted heterocycles useful for treating or preventing hcv infection |
| US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| CA2501365C (en) | 2002-10-30 | 2011-05-31 | Merck & Co., Inc. | Inhibitors of akt activity |
| CA2511178A1 (en) * | 2002-12-20 | 2004-07-15 | Migenix Corp. | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| WO2004058683A2 (en) * | 2002-12-20 | 2004-07-15 | Migenix Corp. | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| WO2004058722A1 (en) * | 2002-12-24 | 2004-07-15 | Arena Pharmaceuticals, Inc. | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| EP1620095A4 (de) | 2003-04-24 | 2009-04-01 | Merck & Co Inc | Hemmer der akt aktivität |
| EP1631546A1 (de) * | 2003-04-25 | 2006-03-08 | H. Lundbeck A/S | Substituierte indolin- und indolderivate |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| WO2005002673A1 (en) * | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
| RS20060035A (sr) * | 2003-07-22 | 2008-08-07 | Arena Pharmaceuticals Inc., | Derivati diaril i arilheteroaril uree kao modulatori receptora 5-ht2a serotonina korisni u profilaksi i lečenju poremećaja u vezi sa njima |
| US7517900B2 (en) | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| WO2005103011A1 (en) | 2004-03-23 | 2005-11-03 | Arena Pharmaceuticals, Inc. | Processes for preparing substituted n-aryl-n’-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| PT1789390E (pt) * | 2004-09-02 | 2012-02-08 | Genentech Inc | Inibidores de piridilo da sinalização de hedgehog |
| PE20061130A1 (es) * | 2004-11-19 | 2007-01-05 | Arena Pharm Inc | Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a |
| US20080015223A1 (en) * | 2004-12-03 | 2008-01-17 | Arena Pharmaceuticals, Inc. | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto |
| EP1843762A1 (de) * | 2005-01-19 | 2007-10-17 | Arena Pharmaceuticals, Inc. | Diaryl- und arylheteroaryl-harnstoff-derivate als modulatoren des 5-ht2a-serotoninrezeptors zur prophylaxe oder behandlung progressiver multifokaler leukoencephalopathie |
| WO2007026920A2 (en) * | 2005-09-02 | 2007-03-08 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| JP2009514915A (ja) | 2005-11-08 | 2009-04-09 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | インデン誘導体、それらの製造および薬剤としての使用 |
| CN101479261A (zh) | 2006-05-18 | 2009-07-08 | 艾尼纳制药公司 | 3-吡唑基-苯甲酰胺-4-醚、其仲胺及其衍生物作为5-ht2a血清素受体的调节剂用于治疗与其相关的病症 |
| MX349156B (es) | 2006-05-18 | 2017-07-14 | Arena Pharm Inc | Formas cristalinas y procesos para la preparacion de fenil-pirazoles utiles como moduladores del receptor de serotonina 5-ht2a. |
| ES2536762T3 (es) | 2006-05-18 | 2015-05-28 | Arena Pharmaceuticals, Inc. | Aminas primarias y sus derivados como moduladores del receptor de la serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con este |
| EP2041116A1 (de) * | 2006-07-07 | 2009-04-01 | Boehringer Ingelheim International GmbH | Phenyl substituierte heteroaryl-derivate und deren verwendung als antitumormittel |
| EP1884515A1 (de) | 2006-07-31 | 2008-02-06 | Laboratorios del Dr. Esteve S.A. | Substituierte Indanylsulfonamid-Verbindungen, ihre Herstellung und Verwendung als Medikament |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| WO2008058341A1 (en) | 2006-11-15 | 2008-05-22 | Cytopia Research Pty Ltd | Inhibitors of kinase activity |
| US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
| EP2520561B1 (de) | 2007-06-08 | 2016-02-10 | MannKind Corporation | IRE-1a-Inhibitoren |
| US20100240657A1 (en) * | 2007-07-02 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Chemical compounds |
| CL2008001943A1 (es) * | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
| EP2016943B1 (de) | 2007-07-19 | 2011-02-23 | Laboratorios del Dr. Esteve S.A. | Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente |
| EP2190844B3 (de) | 2007-08-15 | 2013-07-17 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridinderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich für die behandlung von damit in zusammenhang stehenden erkrankungen eignen |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US8778929B2 (en) | 2008-09-29 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Substituted heteroaryl inhibitors of B-RAF |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| RS57110B1 (sr) | 2008-10-28 | 2018-06-29 | Arena Pharm Inc | Sastavi modulatora 5-ht2a serotoninskog receptora korisni za tretiranje poremećaja povezanih sa njim |
| CA2749783A1 (en) | 2009-01-16 | 2010-07-22 | Massachusetts Institute Of Technology | Diagnosis and treatment of autism spectrum disorders |
| WO2011035186A1 (en) * | 2009-09-17 | 2011-03-24 | Vanderbilt University | Substituted heteroarylamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
| US8980891B2 (en) | 2009-12-18 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| EP2552905B1 (de) | 2010-03-26 | 2016-10-05 | Boehringer Ingelheim International GmbH | Inhibitoren der B-Raf Kinase |
| JP5871897B2 (ja) | 2010-03-26 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジルトリアゾール |
| US9751847B2 (en) | 2010-10-14 | 2017-09-05 | University Of Utah Research Foundation | Methods and compositions related to neuroactive thiazoline compounds |
| US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| IN2014CN02332A (de) * | 2011-09-29 | 2015-06-19 | Ono Pharmaceutical Co | |
| EP2763532B1 (de) | 2011-10-05 | 2018-09-19 | The Board of Trustees of the Leland Stanford Junior University | Pi-kinaseinhibitoren mit anti-infektiver breitspektrumaktivität |
| US9926309B2 (en) | 2011-10-05 | 2018-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| SG11201505631PA (en) | 2013-01-23 | 2015-08-28 | Astrazeneca Ab | Chemical compounds |
| AU2014353150A1 (en) | 2013-11-19 | 2016-07-07 | Vanderbilt University | Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5 |
| US9533982B2 (en) | 2014-03-20 | 2017-01-03 | Vanderbilt University | Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators |
| US9550778B2 (en) | 2014-10-03 | 2017-01-24 | Vanderbilt University | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 |
| AU2016276966A1 (en) | 2015-06-12 | 2018-01-18 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder |
| PT3319959T (pt) | 2015-07-06 | 2021-12-06 | Alkermes Inc | Inibidores hetero-halo de histona desacetilase |
| WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| EP3322415A4 (de) | 2015-07-15 | 2019-03-13 | Axovant Sciences GmbH | Diaryl- und arylheteroaryl-harnstoff-derivate als modulatoren des 5-ht2a-serotoninrezeptors zur prophylaxe und behandlung von halluzinationen im zusammenhang mit einer neurogenerativen erkrankung |
| EP3353182A1 (de) | 2015-09-24 | 2018-08-01 | Pfizer Inc | Tetrahydropyrano[3,4-d][1,3]oxazin-derivate und deren verwendung als bace-inhibitoren |
| US10300155B2 (en) | 2015-12-31 | 2019-05-28 | Washington University | Alpha-synuclein ligands |
| ES3010661T3 (en) | 2016-02-26 | 2025-04-04 | Univ Leland Stanford Junior | Pi-kinase inhibitors with anti-infective activity |
| MX394242B (es) | 2017-01-11 | 2025-03-24 | Rodin Therapeutics Inc | Inhibidores biciclicos de histona desacetilasa |
| MX2020001484A (es) | 2017-08-07 | 2020-08-20 | Rodin Therapeutics Inc | Inhibidores bicíclicos de la histona desacetilasa. |
| WO2019152711A1 (en) | 2018-01-31 | 2019-08-08 | Diciphera Pharmaceuticals Llc. | Combination therapy for the treatment of gastrointestinal stromal tumors |
| KR102708050B1 (ko) | 2018-01-31 | 2024-09-24 | 데시페라 파마슈티칼스, 엘엘씨. | 비만 세포증의 치료를 위한 병용 요법 |
| EP3941909A4 (de) | 2019-03-21 | 2023-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Pi4-kinase-inhibitoren und verfahren zur verwendung davon |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| CA3150433A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| CN115243681B (zh) | 2019-12-30 | 2024-08-16 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
| FI4084778T3 (fi) | 2019-12-30 | 2023-12-18 | Deciphera Pharmaceuticals Llc | Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi |
| AU2021384833A1 (en) * | 2020-11-18 | 2023-06-15 | Elanco Tiergesundheit Ag | N-(2,3-dihydro-1,4-benzoxazin-4-yl)-3-isopropyl-7-(2,3,5-trifluorophenyl)benzo-thiophene-2-carboxamide derivatives and similar compounds for the treatment of heartworm infections |
| WO2023114313A1 (en) * | 2021-12-15 | 2023-06-22 | Delix Therapeutics, Inc. | Phenoxy and benzyloxy substituted psychoplastogens and uses thereof |
| WO2023114325A1 (en) * | 2021-12-15 | 2023-06-22 | Delix Therapeutics, Inc. | Constrained amine psychoplastogens and uses thereof |
| AU2022415426A1 (en) * | 2021-12-15 | 2024-07-25 | Delix Therapeutics, Inc. | Fused pyrrolidine psychoplastogens and uses thereof |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994004533A1 (en) * | 1992-08-20 | 1994-03-03 | Smithkline Beecham Plc | Condensed indole derivatives as 5ht2c and 5ht2b antagonists |
| WO1996023783A1 (en) * | 1995-02-02 | 1996-08-08 | Smithkline Beecham Plc | Indole derivatives as 5-ht receptor antagonist |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE581862A (de) * | 1958-08-22 | |||
| SE370866B (de) * | 1968-03-21 | 1974-11-04 | Ciba Geigy Ag | |
| US5328922A (en) * | 1990-09-13 | 1994-07-12 | Beecham Group P.L.C. | Indole ureas as 5 ht receptor antagonist |
| GB9306460D0 (en) * | 1993-03-29 | 1993-05-19 | Smithkline Beecham Plc | Novel compounds |
| GB9313913D0 (en) * | 1993-07-06 | 1993-08-18 | Smithkline Beecham Plc | Novel compounds |
-
1996
- 1996-01-26 CN CNB961927771A patent/CN1151147C/zh not_active Expired - Fee Related
- 1996-01-26 DK DK96902259T patent/DK0808312T3/da active
- 1996-01-26 RO RO97-01439A patent/RO115522B1/ro unknown
- 1996-01-26 FI FI973205A patent/FI973205L/fi unknown
- 1996-01-26 SK SK1038-97A patent/SK103897A3/sk unknown
- 1996-01-26 EA EA199700156A patent/EA000304B1/ru not_active IP Right Cessation
- 1996-01-26 PL PL96321706A patent/PL184490B1/pl not_active IP Right Cessation
- 1996-01-26 AP APAP/P/1997/001036A patent/AP657A/en active
- 1996-01-26 CA CA002212061A patent/CA2212061A1/en not_active Abandoned
- 1996-01-26 HU HU9901115A patent/HU223601B1/hu not_active IP Right Cessation
- 1996-01-26 BR BR9607016A patent/BR9607016A/pt not_active Application Discontinuation
- 1996-01-26 NZ NZ301265A patent/NZ301265A/xx unknown
- 1996-01-26 DE DE69610822T patent/DE69610822T2/de not_active Expired - Fee Related
- 1996-01-26 TR TR97/00749T patent/TR199700749T1/xx unknown
- 1996-01-26 AU AU46646/96A patent/AU699727B2/en not_active Ceased
- 1996-01-26 AT AT96902259T patent/ATE197300T1/de not_active IP Right Cessation
- 1996-01-26 ES ES96902259T patent/ES2151652T3/es not_active Expired - Lifetime
- 1996-01-26 SI SI9630257T patent/SI0808312T1/xx unknown
- 1996-01-26 WO PCT/EP1996/000368 patent/WO1996023783A1/en not_active Ceased
- 1996-01-26 JP JP8523247A patent/JPH10513442A/ja not_active Ceased
- 1996-01-26 CZ CZ19972445A patent/CZ294097B6/cs not_active IP Right Cessation
- 1996-01-26 EP EP96902259A patent/EP0808312B1/de not_active Expired - Lifetime
- 1996-01-26 KR KR1019970705276A patent/KR19980701879A/ko not_active Withdrawn
- 1996-01-26 US US08/875,506 patent/US5990133A/en not_active Expired - Fee Related
- 1996-01-26 PT PT96902259T patent/PT808312E/pt unknown
- 1996-01-29 AR ARP960101185A patent/AR002705A1/es unknown
- 1996-01-31 MA MA24147A patent/MA23792A1/fr unknown
- 1996-01-31 MY MYPI96000370A patent/MY132229A/en unknown
- 1996-02-01 IL IL11699896A patent/IL116998A/en not_active IP Right Cessation
-
1997
- 1997-08-01 BG BG101806A patent/BG101806A/xx unknown
- 1997-08-01 OA OA70058A patent/OA10502A/en unknown
- 1997-08-01 NO NO19973543A patent/NO313520B1/no unknown
- 1997-10-16 US US09/359,606 patent/US6235758B1/en not_active Expired - Fee Related
-
2000
- 2000-12-13 GR GR20000402763T patent/GR3035075T3/el not_active IP Right Cessation
-
2001
- 2001-01-22 US US09/767,245 patent/US6638953B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994004533A1 (en) * | 1992-08-20 | 1994-03-03 | Smithkline Beecham Plc | Condensed indole derivatives as 5ht2c and 5ht2b antagonists |
| WO1996023783A1 (en) * | 1995-02-02 | 1996-08-08 | Smithkline Beecham Plc | Indole derivatives as 5-ht receptor antagonist |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP657A (en) | Indole derivatives as 5-HT receptor antagonist. | |
| US7504401B2 (en) | Anti-cancer agents and uses thereof | |
| US6310079B1 (en) | Benzimidazole cyclooxygenase-2 inhibitors | |
| SK282708B6 (sk) | Derivát piperazínu so selektivitou pre D-4 receptor, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje | |
| EA031076B1 (ru) | Ингибиторы протеинкиназы | |
| WO2003051366A2 (en) | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer | |
| EP0788499A1 (de) | Z.n.s.-wirksame pyridinylharnstoffderivate | |
| WO1997008167A1 (en) | 5ht2c and 5ht2b antagonists | |
| CN100402521C (zh) | 4-咪唑啉-2-酮化合物 | |
| US7906533B2 (en) | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | |
| JP5069119B2 (ja) | 血管内皮成長因子（ｖｅｇｆ）受容体キナーゼインヒビターとしてのニコチンアミドピリジンウレア | |
| CA2470214A1 (en) | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer | |
| EP3986885B1 (de) | Substituierte pyrrolidinamide iv | |
| HK1003883B (en) | Indole derivatives as 5-ht receptor antagonist | |
| CA2654515A1 (en) | Substituted 3-cyanopyridines as protein kinase inhibitors | |
| MXPA97005992A (en) | Indol derivatives as receptor antagonists5 |